분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-07-28 19:24:54 , Hit : 828
 FDA approves hepatitis C drugs from AbbVie, Bristol-Myers

Thomson Reuters  
Edition:
U.S.

Health  |  Fri Jul 24, 2015 5:43pm EDT
Related:  Health  

AbbVie, Bristol-Myers get FDA nod for hep C treatments

The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections.

The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 infections.

About 2.7 million Americans are infected with HCV, of which 10 percent are genotype 3. Genotype 4 is considered among the least common, according to the Centers for Disease Control and Prevention.

Both treatments do not require the co-administration of older antivirals, the regulator said.

The viral disease causes inflammation of the liver that can lead to diminished function or failure of the organ.

Technivie comprises three drugs that are included in Viekira Pak, AbbVie's regimen for the most common form of HCV infection - genotype 1. (1.usa.gov/1gSuFvU)

Technivie is the first regimen approved to safely and effectively treat genotype 4, while Daklinza is the first for genotype 3, the FDA said.

The regulator has approved the use of Daklinza in combination with Gilead Sciences Inc's Sovaldi. (1.usa.gov/1VFlkaX)

Viekira Pak raked in sales of $231 million in the first quarter 2015, while Gilead's Sovaldi brought in $972 million in the same period.

(The story corrects paragraph six to say Technivie "comprises three drugs that are included in Viekira Pak", not "includes the same cocktail of drugs that comprise Viekira Pak")


(Reporting by Samantha Kareen Nair in Bengaluru; Editing by Kirti Pandey and Saumyadeb Chakrabarty)







1067   혈액 암과 면역세포의 DNA 편집의 관계  이성욱 2015/09/14 881
1066   아스피린이 암의 면역요법 효과 증대  이성욱 2015/09/08 770
1065   처음으로 밝혀진 수면부족과 감기 간의 관련성  이성욱 2015/09/03 806
1064   알츠하이머 질환에 대한 항체약물의 가능성  이성욱 2015/07/30 953
1063   DNA 앰블런스  이성욱 2015/07/30 898
1062   유전자 넉아웃을 보상하는 또 다른 유전자  이성욱 2015/07/30 1137
  FDA approves hepatitis C drugs from AbbVie, Bristol-Myers  이성욱 2015/07/28 828
1060   항-PD-1 항체에 저항성을 보이는 기작  이성욱 2015/07/28 995
1059   항체 함암제를 테스트할 수 있는 인간화 생쥐 모델  이성욱 2015/07/28 1247
1058   생명과학 연구에서 암컷쥐가 필요한 이유  이성욱 2015/07/23 907
1057   제 3 자의 혈액을 이용한 T 세포 면역치료  이성욱 2015/07/22 1001
1056   Gene Therapy Allows Beethoven Mouse to Hear  이성욱 2015/07/10 774
1055    기능 향상에 효과를 입증한 낭포성 섬유증 환자들에 대한 첫번째 유전자 요법  이성욱 2015/07/07 1227
1054   프리온 유사 단백질이 장기 기억을 유지시킨다고?  이성욱 2015/07/06 1260
1053   韓中 연구진, TALEN 기술로 초근육질 돼지 만들어  이성욱 2015/07/02 1113
1052   microRNA가 췌장암 치료제가 될 수 있을까  이성욱 2015/06/30 964
1051   T 세포 면역 치료를 향상시키는 유전자  이성욱 2015/06/29 1923
1050   A single gene turns colorectal cancer cells back into normal tissue in mice  이성욱 2015/06/23 877
1049   프리온 질환을 막는 유전자 돌연변이  이성욱 2015/06/15 902
1048   한국의 MERS가 글로벌 보건을 위협할 수 있을까?  이성욱 2015/06/09 859

[이전 10개] [1].. 11 [12][13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2020 Zeroboard / skin by ROBIN